Tesamorelin side effects and safety context

Tesamorelin's side effects follow directly from what it does: it raises growth hormone and, downstream, IGF-1. Almost everything on its label is either a consequence of GH physiology — fluid retention, joint pain, glucose intolerance — or a consequence of daily subcutaneous injection. Very little of it is idiosyncratic to the molecule.

That makes the profile predictable, which is genuinely reassuring, and it also means the effects are not incidental. They come from the same biology as the intended fat reduction.

The most common adverse reactions occurring in at least 5% of patients, per the EGRIFTA SV prescribing information:

• Arthralgia — joint pain, a classic GH-mediated effect.
• Injection site erythema and pruritus — redness and itching at the site.
• Pain in extremity and myalgia.
• Peripheral edema — fluid retention, which can also present as carpal tunnel-type tingling.

Injection site reactions occurred in 25% of treated patients versus 14% on placebo during the first 26 weeks — a meaningful gap, given that this is a once-daily injection taken indefinitely. Hypersensitivity reactions occurred in 4% of trial participants and are a labeled warning in their own right.

The pooled phase 3 analysis of 806 adults described tesamorelin as "generally well tolerated" over 52 weeks (J Clin Endocrinol Metab 2010; PMID 20554713), and the liver-fat trial reported more localised injection site complaints in the tesamorelin group, none judged serious (Lancet HIV 2019; PMID 31611038).

Growth hormone opposes insulin, so glucose intolerance is the metabolic liability inherent to any GH-raising therapy. The label puts numbers on it: 5% of tesamorelin-treated patients developed an HbA1c of 6.5% or higher versus 1% on placebo, with a hazard ratio of 3.3 for developing diabetes.

This sits in tension with the trial-level finding that fasting glucose and HbA1c did not differ between groups in the liver-fat study, and that the phase 3 programme found no clinically meaningful differences in glucose parameters. Both are true. The averages moved little; a minority of individuals crossed a diagnostic threshold. Averages and tails answer different questions, and a label warns about the tail.

The responder analysis adds a wrinkle: participants who achieved at least 8% VAT reduction had better preservation of glucose and HbA1c than non-responders (p<0.001 at 52 weeks), suggesting the visceral fat loss and the GH effect push in opposite metabolic directions (Clin Infect Dis 2012; PMID 22495074).

The label lists four contraindications:

• Disruption of the hypothalamic-pituitary axis from hypophysectomy, pituitary tumour or surgery, head irradiation, or head trauma.
• Active malignancy — the GH/IGF-1 axis is a growth signalling pathway, and pre-existing cancers must be inactive before treatment.
• Known hypersensitivity to tesamorelin or any excipient, including mannitol.
• Pregnancy.

Beyond those, the label directs clinicians to monitor IGF-1 and consider discontinuation if levels remain persistently elevated — a requirement that exists precisely because the drug works by raising them. IGF-1 rose significantly in the phase 3 programme (J Acquir Immune Defic Syndr 2010; PMID 20101189).

• Population. The safety dataset comes from adults with HIV-associated lipodystrophy on antiretroviral therapy. It does not describe healthy adults using the drug for body composition.
• Cardiovascular safety. The label states plainly that long-term cardiovascular safety has not been established.
• Product identity. EGRIFTA SV and EGRIFTA WR are explicitly not substitutable — different strengths, doses, reconstitution, and storage. Research-grade "tesamorelin" is neither, and carries purity and concentration uncertainty on top of everything above.
• Monitoring is the mechanism of safe use. IGF-1 and glucose surveillance are what convert a predictable side-effect profile into a managed one, and they require a prescriber.